Working Together, Finding Cures

New Paid Research Opportunity: Bone Marrow Donors Needed

Your Blood Institute is partnering with a start-up drug company to provide mesenchymal stromal cells (MSCs) for age-related disease research. Researchers currently need individuals willing to donate bone marrow.  

A Florida-based research firm focused on combating aging and age-related disease is conducting clinical trials that center on the collection of MSCs, extracted from bone marrow.  MSCs are a type of stem cell found in bone marrow that have the ability to transform into different bone or tissue types within the body.

Potential participants should be between the ages of 18 and 45, non-smokers, in good health, and weigh less than 250 pounds.  Donors should live in the Oklahoma City metro area.  Please note that the procedure will occur at an outpatient surgery center in Oklahoma City and pain will feel similar to falling and bruising your hip.  

Participants are eligible to receive $500 in compensation.  If you're interested, please make sure you complete your BioProfile on the Bio-Linked website, and mark "Bone Marrow" under your donation preferences.

Read more news from Bio-Linked™

Subscribe to our quarterly newsletter

A Guide: How to Participate in Bio-Linked Studies

In order to be eligible to participate in Bio-Linked studies, you must:
  • Fully complete your BioProfile on the Bio-Linked website  
  • Accept research opportunities on your BioProfile  
  • Under preferences, be sure to note your preferred method of contact, and mark the donation types you are willing to offer (see photo below)
Bio-Linked will use the information in completed profiles to determine if a potential participant meets the requirements for the research study.  Bio-Linked™ will contact you with potential research opportunities.  
Through Bio-Linked™ and Bio-Sharing™, participating blood centers provide the blood cells necessary to support breakthrough studies could lead to new treatments and cures.  

Oklahoma Blood Institute Receives Research Award to Fund Further Studies

As reported by Business Wire

Biological Industries USA Announces Initial Winners of MSC Research Awards

Grants totaling over $65,000 to be issued to scientists working with mesenchymal stem cells for treatment of injury and disease

CROMWELL, Conn.--(BUSINESS WIRE)--Biological Industries USA (BI-USA), a division of Biological Industries Beit Haemek Israel (BI) and providers of premium cGMP cell culture media and media manufacturing services to the academic, biotech, and pharmaceutical industries, announces the initial winners of its MSC Research Award, which was unveiled in January. The winners are scientists advancing the fields of cellular therapy and mesenchymal stem/stromal cell (MSC)-based research. The awards, totaling over $65,000 worth of BI-USA products and services, will fund studies aimed at creating xeno-free cGMP MSC Master Cell Banks, isolating and expanding MSCs from novel sources, manufacturing MSCs with increased immunomodulatory efficacy, and modifying MSCs to improve their ability to avoid immune cell attack and eventual rejection after transplantation.

The award recipients for the current round of funding include: Darren Hickerson, MS, MDiv, Associate Director of Manufacturing, Wake Forest Institute for Regenerative Medicine (WFIRM); Jennifer Chain, PhD, Science Officer for Cellular Therapies, Oklahoma Blood Institute; James Ankrum, PhD, Assistant Professor, Biomedical Engineering, University of Iowa; and Yan Li, MD, Project Staff, Cleveland Clinic.

“The BI-USA MSC Award program recognizes the importance of using mesenchymal cells to advance much-needed translational research, which we feel can be accelerated by using defined, xeno-free, serum-free systems,” said Tanya Potcova, CEO of BI-USA. “We are very excited to watch the progress and are pleased to support each award winner’s important research as they move forward.”

About Biological Industries (BI)

Biological Industries ( is one of the world’s leading and trusted suppliers to the life sciences industry, with over 35 years’ experience in cell culture media development and GMP manufacturing. BI’s products range from classical cell culture media, to supplements and reagents for stem cell research and cell therapy applications, to serum and serum-free media products. BI is committed to a Culture of Excellence through advanced manufacturing and quality-control systems, regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training, and R&D capabilities.

About Biological Industries USA (BI-USA)

Biological Industries USA ( is the US commercialization arm of BI, with facilities in Cromwell, Connecticut. Members of the BI-USA team share expertise and a history of innovation and success in the development of leading-edge technologies in stem cell research, cellular reprogramming, and regenerative medicine.

To receive ongoing BI communications, please join the email list or connect with the company at